Zofran and generics (ondansetron) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board
09 August 2012
Important Safety Information communication from GlaxoSmithKline on ondansetron (Zofran and generics) and dose-dependent QT interval prolongation – new dose restriction for intravenous (IV) use.
Important Safety Information - Zofran and generics
Summary of Product Characteristics
Package Leaflet: Information for the User